ArticlePloS one2026
The anti-angiogenic and anti-proliferative activity of n-benzoyl-3-phenyl isoserine derivative containing 1,2,3-triazole and quinoline rings.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the biggest causes of death globally is cancer, which develops tumors characterized by angiogenesis and excessive cell proliferation. Cancer treatments targeting these pathways, especially those involving vascular endothelial growth factor, have had encouraging results. This study examined the anti-angiogenic and anti-proliferative properties of a phenyl isoserine derivative compound. The ex vivo anti-angiogenic activity was examined by rat aorta ring (RAR) and in vivo chorioallantoic membrane (CAM) assays. The in vitro anti-proliferative properties of the compound were analyzed utilizing Human umbilical vein endothelial (HUVEC), colon cancer, and breast cancer cell lines. Quantitative real-time PCR was used to measure gene expression of vascular endothelial growth factor receptor 2 (VEGFR-2) gene. An evaluation was conducted on the compound's SwissADME profile, molecular docking, and molecular dynamics simulations against the VEGFR-2 receptor. The phenyl isoserine derivative demonstrated significant anti-angiogenic activity in both the RAR and CAM assays, with a half-maximal inhibitory Concentration (IC50) value of 18.91 μg/mL in the RAR assay. The compound also exhibited anti-proliferative effects against HUVEC, colon cancer, and breast cancer cells, with IC50 values of 68.85, 124.75, and 112.31 μg/mL, respectively. The results of the Real-Time PCR test showed that at a concentration of 200 μg/mL, there was a significant decrease in the expression of the VEGFR-2 gene in Kaposi's Sarcoma (KS) cells. The compound exhibited membrane permeability and dispersion, as expected based on the SwissADME profile, with a consensus log P o/w value of 3.14, while also indicating potential cytochrome P450 enzyme inhibition and poor water solubility (Log Sw value: -8.34). Molecular docking (MD) studies revealed a higher PLP fitness score (91.496) for the compound compared to axitinib (78.748), suggesting a favorable binding to VEGFR-2. However, axitinib demonstrated a more negative binding energy (-14.548 kcal/mol vs. -7.715 kcal/mol), reflecting stronger energetic stabilization under docking conditions. Molecular dynamics simulations showed that ligand exhibits stable binding and induces greater structural stabilization of the target protein compared to axitinib, suggesting its potential as a more effective VEGFR-2 inhibitor. The phenyl isoserine derivative was found to have a potent inhibitory effect on angiogenesis and VEGFR-2 gene activity, indicating it could be a promising candidate for anti-cancer medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.